| 摘要 |
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and is meant for treating CD20 expressing tumours. A CD20 antibody molecule merged with a IL2 molecule is disclosed. The antibody contains modified variable parts of a heavy and a light chain. Disclosed also is a pharmaceutical composition for treating a CD20 expressing tumour, which contains a merged polypeptide of the CD20 antibody, as well as a DNA molecule which codes the said merged polypeptide. ^ EFFECT: invention enables to lower immunogenicity of the modified anti-CD20 antibody compared to unmodified molecules and increase anti-tumour activity with respect to CD20. ^ 15 cl, 17 dwg, 3 tbl, 8 ex |
